IDH1 and central nervous system cancer: Especially in MGMT methylated glioblastomas, and also in IDH mutated gliomas, treatment-induced changes on conventional magnetic resonance imaging (MRI) are not always easily distinguishable from true tumor progression, a phenomenon termed pseudoprogression (10, 11).